Welcome to MolDiag-PaCa
1. Heidenblut, A. M., Luttges, J., Buchholz, M., Heinitz, C., Emmersen, J., Nielsen, K. L., Schreiter, P., Souquet, M., Nowacki, S., Herbrand, U., Kloppel, G., Schmiegel, W., Gress, T., and Hahn, S. A. aRNA-longSAGE: a new approach to generate SAGE libraries from microdissected cells. Nucl. Acids. Res., 32: e131-, 2004.

2. Volmer M.W., Radacz, Y., Hahn, S.A., Klein-Scory, S., Stühler, K., Zapatka, M., Schmiegel, W., Meyer, H.E., and Schwarte-Waldhoff, I. Tumor suppressor Smad4 mediates down-regulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a “secretome” analysis. Proteomics, 4: 1324-1334, 2004.

3. Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., Gerdes, B., Kress, R., Ziegler, A., Raeburn, J. A., Campra, D., Grutzmann, R., Rehder, H., Rothmund, M., Schmiegel, W., Neoptolemos, J. P., and Bartsch, D. K. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst, 95: 214-221, 2003.

4. Schwarte-Waldhoff, I., Volpert, O.V., Bouck, N.P., Sipos, B., Hahn, S.A., Klein-Scory, S., Lüttges, J., Klöppel, G., Graeven, U., Eilert-Micus, C., Hintelmann, A., Schmiegel, W., Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A. 2000 97(17):9624-9.

5. Lüttges, J., Galehdari, H., Bröcker, V., Schwarte-Waldhoff, I., Henne-Bruns, D., Klöppel, G., Schmiegel, W., and Hahn, S. A. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol, 158: 1677-1683, 2001.

1. Bassi C, Salvia R, Molinari E, Biasutti C, Falconi M, Pederzoli P: Management of 100 consecutive cases of pancreatic serous cystadenoma: wait for symptoms and see at imaging or vice versa? World J Surg 2003, 27:319-323

2. Bassi C, Salvia R, Gumbs AA, Butturini G, Falconi M, Pederzoli P: The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3. Langenbecks Arch Surg 2002, 387:281-285

3. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585

4. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210

5. Salvia R, Fernandez-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, Pederzoli P, Warshaw AL: Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004, 239:678-685

1. Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, Bassi C, Lemoine NR, Scarpa A. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001;84:253-62.

2. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, Pesci A, Baron A, Lissandrini D, Rindi G, Grigolato P, Pederzoli P, Scarpa A. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 2001;61:285-92.

3. Cattaneo M, Orlandini S, Beghelli S, Moore PS, Sorio C, Bonora A, Bassi C, Talamini G, Zamboni G, Orlandi R, Menard S, Bernardi LR, Biunno I, Scarpa, A. SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo. Oncogene 2003;22:6359-68.

4. Laudanna C, Sorio C, Tecchio C, Butcher EC, Bonora A, Bassi C, Scarpa A. Motility analysis of pancreatic adenocarcinoma cells reveals a role for the atypical zeta isoform of protein kinase C in cancer cell movement. Lab Invest 2003;83:1155-63.

5. Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M, Scarpa A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta 2004;1693:167-76.


1) Rodolosse A, Chalaux E, Adell T, Hag�ge H, Skoudy A, Real FX. PTF-1a/p48 transcription factor couples cell proliferation to cell differentiation in the exocrine pancreas. Gastroenterology 2004; 127:937-949.

2) Aguilar S, Corominas JM, Malats N, Dufresne M, Real FX, Navarro P. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 2004; 165:1129-1139.

3) Real FX. A "catastrophic" hypothesis for pancreas cancer progression. Gastroenterology 2003; 124:1958-1964.

4) Real FX, Malats N, Lesca G, Porta M, Chopin S, Lenoir GM, Sinilnikova O, for the PANKRAS II Study group. Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreas cancer. Gut 2002; 50:653-657.

5) Porta M, Malats N, Jariod M, Grimalt JO, Rif� J, Carrato A, Guarner L, Salas A, Santiago-Silva M, Corominas JM, Andreu M, Real FX for the PANKRAS II Study Group. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. Lancet 1999; 354:2125-2129.

6) Vineis P, Malats N, Lang M, d�Errico A, Caporaso N, Cuzick J, Boffetta P. Metabolic polymorphisms and susceptibility to cancer. IARC Scientific Publications, 1999, ISBN: 9283221486.